Who owns GH Research PLC (GHRS)? Elite investor 13F holders

3 tracked elite investors reported holding GH Research PLC as of 2026-06-30, including Tudor Investment, D.E. Shaw, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Tudor InvestmentGH RESEARCH PLCSHARE2026-06-302026-08-14 00:00:00921393.00 USD34278.000000SharesaddOriginal filing
D.E. ShawGH RESEARCH PLCSHARE2026-06-302026-08-14 00:00:00681274.00 USD25345.000000SharesbuyOriginal filing
Renaissance Technologies LLCGH RESEARCH PLCSHARE2026-06-302026-08-13 00:00:000.00 USD0.000000SharesexitedOriginal filing
Ancora Advisors / Ancora HoldingsGH RESEARCH PLCSHARE2026-06-302026-08-14 00:00:007634.00 USD284.000000SharesholdOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown